KCC2 Enhancer Restores Inhibitory Neurotransmission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic pain associated with malignant growth disorders lack effective and safer alternatives to opioids, as they fail to restore physiologic GABA-ergic transmission due to attenuated KCC2 expression in spinal cord dorsal horn neurons, leading to excitation/inhibition imbalance.
Innovation Solution
Identification and use of compounds that enhance K+/Cl-cotransporter (KCC2) gene expression, specifically GSK3β inhibitors like Kenpaullone (KP), to increase chloride ion efflux and restore KCC2 function, thereby normalizing inhibitory neurotransmission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioids are used to treat chronic pain associated with malignant growth disorders, then pain relief is achieved, but safety and effectiveness are compromised due to lack of safer alternatives
Solution Approach 1:
The invention changes the biochemical parameter of chloride ion concentration in neurons by enhancing KCC2 transporter function. This restores the excitation/inhibition balance in pain pathways, providing an alternative mechanism for pain relief that does not involve opioid receptors, thereby avoiding opioid side effects while maintaining pain treatment effectiveness
Solution Approach 2:
The invention introduces GSK3β inhibitors as intermediary compounds that indirectly restore KCC2 function. These compounds act as mediators between the administered substance and the KCC2 transporter, enhancing chloride extrusion and restoring inhibitory neurotransmission without directly activating opioid pathways, thus providing safer pain relief
2Reliability
If KCC2 expression is restored to normalize inhibitory neurotransmission, then pathologic pain is reduced, but the underlying mechanism requires new therapeutic approaches beyond current treatments
Solution Approach 1:
The invention applies preliminary action by using GSK3β inhibitors to prevent further degradation of KCC2 function and to proactively restore chloride extrusion capacity before pain pathways become fully dysregulated. This preventive-restorative approach addresses the root cause of inhibitory neurotransmission failure in chronic pain, normalizing GABAergic function before complete circuit malfunction occurs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce pathologic pain by enhancing KCC2 expression and function, providing a safer and more effective analgesic solution for chronic pain conditions without affecting motor stamina or coordination.
Implementation Method 1
identification of compounds that enhance K+/Cl-cotransporter (Kcc2/KCC2; Kcc2—rodent gene; KCC2—human gene) gene expression
Implementation Method 2
KCC2 continuously extrudes chloride ions, thus ensuring that intracellular levels of chloride ions remain low as required for inhibitory GABA-ergic neurotransmission
Data Source
AI summary
The present disclosure describes, in part, compositions and methods for treating pathologic pains associated with malignant growth disorders by administering a therapeutically effective amount of K+/Cl-cotransporter (Kcc2/KCC2) gene expression enhancer to a subject in need.